Montpellier, November 28, 2022 at 6:00 p.m. – MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary technology for the administration of active ingredients in nano micelles by the oral route, Aonys®, is taking part in the 15th annual Clinical Trials conference on Alzheimer’s Disease (CTAD) dedicated to therapeutic trials on Alzheimer’s disease which takes place in San Francisco from November 29 to December 2, 2022 and presents a poster on its drug candidate in the process of Phase II clinical study) NanoLithium® AD .
The Clinical Trials on Alzheimer’s Disease (CTAD) conference is an International Congress entirely devoted to therapeutic trials on Alzheimer’s disease. Leading leaders in Alzheimer’s disease research, from industry and academia, are coming together and forming partnerships with the goal of accelerating the development of effective treatments to fight the disease.